Shares of Johnson & Johnson suffered another blow Friday related to product safety, as the consumer-products giant’s recall of some baby powder — after tests revealed traces of asbestos — comes despite the company’s repeated assurances of its safety.

The stock JNJ, +0.68% sank 6.2% in active afternoon trading to suffer the biggest one-day drop in 10 months. Volume ballooned to 28.9 million shares, more than four times the full-day average of about 7.1 million shares.

The selloff was enough to make the stock the biggest loser in the SPDR Health Care Select Sector exchange-traded fund XLV, +1.60% and the second-biggest decliner in Dow Jones Industrial Average DJIA, +1.33% , behind the 6.8% selloff in Boeing Co. BA, +6.83% shares. The price decline of $8.47 was shaved about 57 points off the Dow’s price, which closed down 256 points.

J&J said it was recalling a “single lot” of its Johnson’s Baby Powder, “out of an abundance of caution,” after a U.S. Food and Drug Administration test found “sub-trace levels” of chrysotile asbestos. The company said the contamination, which was no greater than 0.00002%, was found in samples from a single bottle purchased from an unnamed online retailer.

“In parallel, [Johnson & Johnson Consumer Inc.] (JJCI) has immediately initiated a rigorous, thorough investigation into this matter, and is working with the FDA to determine the integrity of the tested sample, and the validity of the test results,” JJCI said in a statement.

The J&J unit emphasized that “at this early stage” of the investigation, JJCI can’t confirm whether the tested product was authentic or counterfeit, or whether the sample was taken from a sealed bottle or if cross-contamination from another product caused a false-positive reading.

The company’s implied skepticism of the FDA’s findings comes as J&J is facing more than 14,000 lawsuits alleging its baby powder and talc products cause cancer, while the company vigorously denies such claims.

Last year, a St. Louis jury ruled that the company had to pay $4.7 billion to 22 women and their families who said the baby powder gave them ovarian cancer.

And last Dec. 14, J&J’s stock plunged 10%, its biggest one-day percentage decline in over 18 years, after Reuters reported the company knew for decades that its baby powder was contaminated with asbestos. The company said at the time that the Reuters report was “false and inflammatory,” and that its baby powder was “safe and asbestos-free.”

J&J continues to deny the claims. On Friday, the company said in a statement:

“JJCI has a rigorous testing standard in place to ensure its cosmetic talc is safe and years of testing, including the FDA’s own testing on prior occasions--and as recently as last month--found no asbestos. Thousands of tests over the past 40 years repeatedly confirm that our consumer talc products do not contain asbestos.”

Analyst Damien Conover at Morningstar said although the recall increases the uncertainty around J&J’s product governance, it doesn’t change his bullish stance on the company as he doesn’t expect the baby powder litigation to have a major impact on its consumer products brands.

“[M]any of the company’s brands are marketed under different names, so any brand damage done to baby powder is unlikely to transfer to other company brands,” Conover wrote in a note to clients. “Also, we expect J&J to pull out all the stops to support the baby powder brand, which should limit brand damage as the firm has a successful track record of defending brands.”

Conover actually raised his stock fair value estimate to $134 from $130, citing increased projections for the company’s late-stage pipeline drugs.

Meanwhile, the recall is the latest setback for J&J regrading product safety, as the company was ordered earlier this month by a Philadelphia jury to pay $8 billion to a Maryland man who said using the company’s antipsychotic Risperdal as a child caused enlarged breasts. The company is also facing multiple claims regarding its role in fueling the opioid crisis.

Don’t miss: Major drug distributors in talks to settle opioid lawsuits for $18 billion.

J&J’s stock has lost 1.1% year to date, while the health-care ETF has gained 6.1% and the Dow industrials has climbed 14.8%.